Norges Bank’s LAVA Therapeutics LVTX Stock Holding History

Norges Bank’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-17,300	Closed	-$263K	–	2237
2021 Q1	$263K	Buy	+17,300	New	+$238K	﹤0.01%	2117

Other funds holding LVTX

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

NIP

Nicholas Investment Partners Rancho Santa Fe, California $1.78B AUM 114.03% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Norges Bank's LVTX Position: Q2 2021 in Review

Norges Bank sold out of LAVA Therapeutics (LVTX) in Q2 2021, closing a stake of 17,300 shares — an estimated $263K sold.

Norges Bank first reported a position in LVTX in Q1 2021 and held it in 1 quarter. The position peaked at $263K in Q1 2021. 18 funds tracked by Wall St. Rank hold LVTX as of Q2 2021.

Norges Bank reported no remaining LAVA Therapeutics position as of Q2 2021 after selling out during the quarter.
Norges Bank sold 17,300 LAVA Therapeutics shares in Q2 2021, an estimated $263K.
Norges Bank first reported a position in LAVA Therapeutics in Q1 2021 and held it in 1 quarter.
Norges Bank's LAVA Therapeutics position peaked at $263K in Q1 2021.
18 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2021.

Based on Norges Bank's 13F filing for Q2 2021, filed 10 Aug 2021.